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ABSTRACT: Differential ion mobility spectrometry (DIMS) can be used
as a filter to remove undesired background ions from reaching the mass
spectrometer. The ability to use DIMS as a filter for known analytes makes
DIMS coupled to tandem mass spectrometry (DIMS−MS/MS) a promising
technique for the detection of cancer antigens that can be predicted by
computational algorithms. In experiments using DIMS−MS/MS that were
performed without the use of high-performance liquid chromatography
(HPLC), a predicted model antigen, GLR (FLSSANEHL), was detected at
a concentration of 10 pM (20 amol) in a mixture containing 94 competing
model peptide antigens, each at a concentration of 1 μM. Without DIMS
filtering, the GLR peptide was undetectable in the mixture even at 100 nM.
Again, without using HPLC, DIMS−MS/MS was used to detect 2 of 3
previously characterized antigens produced by the leukemia cell line
U937.A2. Because of its sensitivity, a targeted DIMS−MS/MS methodology can likely be used to probe for predicted cancer
antigens from cancer cell lines as well as human tumor samples.
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■ INTRODUCTION
Differential ion mobility spectrometry (DIMS) provides a gas-
phase separation of ions prior to mass analysis. DIMS has the
ability to separate isobaric and isomeric species and therefore
can improve the specificity and detection limits of mass
spectrometry-based analyses.1−3 Low electric field ion mobility
separations take advantage of the difference in the collisional
cross-section of ions, which is directly proportional to the low-
field ion mobility.4,5 At low electric fields the mobility of an ion
is independent of the field. However, at high electric fields
(>104 V/cm), the mobility of an ion becomes dependent on
the electric field in a complex function that is still not
understood.4,5 DIMS takes advantage of the change in ion
mobility in high electric fields to separate ions based on the
difference in ion mobility between low and high electric fields.
Differential ion mobility spectrometers are composed of two
parallel electrodes. The gas flow into the mass spectrometer
carries ions through the gap between the DIMS electrodes. In
“transparent” mode, both of the electrodes are held at the same
potential, and all ions are allowed to pass through the device
without an ion mobility separation. In “active” mode, an
asymmetric waveform is applied to the electrodes. The DIMS
waveform alternates between low and high electric fields of
opposing polarity, such that the ions zigzag through the device.
The V0‑P of the DIMS waveform measured during the high
electric field portion is called the dispersion voltage (DV).
Because ions have a different mobility in the high field versus
low field, they are displaced toward one or the other electrodes
during transit through the device. To direct ions of a selected
differential ion mobility into the mass spectrometer, a
compensation voltage (CV) must be applied to one of the
electrodes, which counter balances the displacement due to the
differential mobility. Because high-field ion mobility is not yet
well understood, the optimum CV and DV for a given analyte
are not easily predicted. This makes DIMS currently most
useful for targeted analyses, where optimal DIMS conditions for
the selection of the analyte of interest can be determined prior
to analysis of the real sample. While there is a loss in overall ion
signal using DIMS, the background signal (chemical noise) is
typically reduced to a much greater extent than the analyte
signal because background ions are eliminated through
collisions with the DIMS electrodes while target ions are not.
The net result is an overall increase in signal-to-noise (S/N).
One potential application for DIMS is the identification of
cancer antigens. These antigens consist of a 9−10 amino acid
peptide fragment, derived from a cancer associated protein,
which is complexed to a class I human leukocyte antigen
(HLA) molecule. The peptide/HLA complexes are assembled
in the endoplasmic reticulum and subsequently transported to
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and presented on the cancer cell’s surface. A cytotoxic CD8+ T-
cell expressing a T-cell receptor with high binding affinity for
the specific peptide/HLA complex can kill the antigen-
presenting cells (i.e., cancer cell) through release of cytotoxic
granule proteins.6−8 Because of the high activity and specificity
of cancer-antigen specific CD8+ T-cells and their ability to
persist in patients indefinitely, many forms of cancer
immunotherapy have been developed to harness this approach
in various cancers including melanoma, renal cell carcinoma,
prostate cancer, and leukemia.9−12 The identification of
appropriate peptide antigens is a vital part of the development
of new T-cell therapies because of the complexity and costs
involved with the production and development of these
therapeutics and the risks involved with directing T-cells to
noncancer (i.e., normal tissue) targets.13,14
The majority of cancer antigenic peptides have been
confirmed using nontargeted reverse phase high-performance
liquid chromatography coupled to tandem mass spectrometry
(HPLC−MS) approaches on a complex mixture of antigenic
peptides obtained from a cellular sample.15−20 While this
approach has proven extremely useful for peptide discovery,
nontargeted HPLC−MS preferentially identifies the most
prevalent peptides, which are not necessarily the most
immunogenic.21 In recent years computational algorithms
have been developed to predict which peptides in a protein
are likely to bind specific HLA molecules.22−26 These
algorithms, when combined with the significant advances in
genomics and computational biology, can be used to predict the
relatively small number of antigenic peptides in tumor extracts
that are likely immunogenic and cancer-specific because they
are produced as a result of cancer-specific processes such as
somatic gene mutations, fusions, overexpression, and alternative
splicing.27,28
By employing a computationally predictive cancer-antigen
discovery approach, targeted MS methodologies aimed at
detecting cancer-specific peptide antigens would facilitate the
discovery of high-value cancer peptide antigens. In this study, a
targeted antigen-discovery strategy employing DIMS−MS/MS
was used to identify known cancer-associated antigenic peptides
from a human leukemia cell line without using HPLC.
■ EXPERIMENTAL SECTION
Model Peptide Pool
A panel of 95 “Flashpure” peptides (New England Peptide,
Gardner MA) that had been computationally predicted to bind
with high affinity to HLA-A*0201 (Supplementary Table S-1)
were dissolved in 100% DMSO to a concentration of 20 mM
and subsequently diluted to 1 μM using 50/49.9/0.1 ACN/
H2O/FA (V/V/V) (Sigma-Aldrich, St. Louis, MO) (Supple-
mentary Table S-1). To create a peptide pool, 94 of the 20 mM
peptide solutions in DMSO were combined in equal volumes
and diluted to a final concentration of 1 μM of each peptide in
50/49.9/0.1 ACN/H2O/FA (V/V/V). The 95th peptide, GLR
(amino acid sequence FLSSANEHL), was further diluted using
50/49.9/0.1 ACN/H2O/FA (V/V/V) and spiked into the 94
peptide pool to make 1 μM, 100 nM, 10 nM, 100 pM, 10 pM,
and 1 pM concentrations of GLR peptide solutions.
Leukemia Cell Line Derived Peptide Mixture
The U937 leukemia cell line stably transfected with HLA-
A*0201 (called U937.A2) were grown under sterile conditions
at 37 °C with 5% CO2 in a medium consisting of RPMI 1640
supplemented with 10% heat inactivated (56 °C for 30 min)
fetal bovine serum (FBS), 1% penicillin−streptomycin, and 1%
L-glutamine.29 Four liters of U937.A2 cell culture suspension
was incubated until the live cell density reached ∼7.5 × 105
cells/mL. The cell suspension (approximately 2 to 3 × 109
U937.A2 cells) was centrifuged at 4 °C for 30 min at 1250 rpm
to obtain a cell pellet, and then the pelleted cells were lysed in
20 mM Tris-HCl, pH 8, 150 mM NaCl, 1% (mass/volume) 3-
[(3-cholamidopropyl) dimethylammonio]-1-propanesulfonate
(CHAPS), 1 mM (phenylmethylsulfonyl fluoride), 10 μg/mL
pepstatin, 5 μg/mL aprotinin, and 10 μg/mL leupeptin (Sigma-
Aldrich, St. Louis, MO). The mixture was gently rocked in a
laboratory shaker for 15 min at 4 °C to break up the cells. The
cell lysate was subjected to ultracentrifugation at 40,000 rpm for
1 h to remove cell debris.30 All protein loading and elution
steps were then performed using a Chemyx Fusion 100 syringe
pump (Stafford, TX). The cell pellet consisted of ∼2 × 109 cells
of U937.A2 with each cell estimated to have ∼10,000 HLA-
A*0201 molecules.31,32 For efficient isolation of nearly all the
HLA-A*0201 molecules in the lysate, 100× excess molecules
(3.3 × 10−9 moles) of the anti-HLA-A*0201 antibody, BB7.2,
were introduced into a 5 mL GE Healthcare HiTRAP
recombinant protein A column (Chicago, IL) for the
immobilization. The BB7.2 antibody molecules were recon-
stituted in 200 mM Tris HCl (pH 8) (Sigma-Aldrich, St. Louis,
MO). For effective antibody immobilization, first, the column
was washed with 50 mM Tris (pH 8) for 5 min at 1 mL/min
flow rate. Then, the reconstituted BB7.2 solution (1 mL) was
injected into the column at 0.2 mL/min flow rate for 5 min.
Excess antibody was washed out using 200 mM Tris HCl (pH
8) at 1 mL/min for 5 min.
The HLA-A*0201/peptide complex containing supernatant
was introduced into the BB7.2 antibody immobilized column at
1 mL/min for immunoaffinity capture of HLA-A*0201/peptide
complexes. Then, the column was washed using 50 mM Tris
(pH 8) solution at 0.5 mL/min for 5 min to remove excess cell
lysate in the column. Finally, 0.2 M acetic acid solution (pH 3)
was introduced at a flow rate of 0.5 mL/min for 10 min to elute
the immobilized HLA-A*0201/peptide complexes from the
column surface. The output was collected into 1.5 mL low-
protein binding microcentrifuge tubes. Glacial acetic acid (17.5
M original) was added to the eluate to increase the acetic acid
percentage to 10% to dissociate the HLA-A*0201 from the
peptides. Finally, the peptides were separated from the high
molecular weight proteins by centrifugation at 3220 rpm in 4
°C for 40 min on an Amicon Ultra-3 kDa device (Millipore,
Billerica, MA). The peptide extract was lyophilized for ∼8 h at
40 °C. The lyophilized peptide samples were stored in −80 °C
until they were analyzed by DIMS−MS/MS.
Mass Spectrometry
A Bruker HCT ion trap mass spectrometer was used for these
experiments. The lyophilized samples obtained from the cell
line were reconstituted for electrospray ionization (ESI) in 60
μL of 50/49.9/0.1 ACN/H2O/FA (V/V/V) and were directly
infused for electrospray ionization (ESI) at a flow rate of 2 μL/
min. The scan rate was 26,000 (m/z)/s for all mass spectra. All
MS/MS spectra represent an average of ten to 11 spectra.
Differential Ion Mobility Spectrometry
The ESI emitter was held at ground potential, and a voltage of
−4.25 kV was applied to the custom built planar DIMS
electrode assembly and housing (Figure 1). The two parallel
stainless steel 4 × 10 mm electrodes are separated by a 0.3 mm
gap. The assembly slides onto the glass transfer capillary of the
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source region of the mass spectrometer. A housing is then
oriented around the assembly to reroute the desolvation gas,
which also serves as the carrier gas through the device. The
temperature of the desolvation gas is set to 300 °C in the
instrument software. The residence time for ions in the device
is 0.2 ms.
Ideally, a square wave should be used for DIMS, alternating
between low and high electric fields of opposing polarity.
However, because of the high power requirements of high-
voltage, high-frequency square waves, most DIMS waveforms
are bisinusoidal, approximating a square wave (Figure 2).33 In
these experiments the waveform generator output a sinusoidal
wave at 2 MHz and a lower amplitude sinusoidal wave at 4
MHz, phase shifted about 90°. Each sinusoidal wave is applied
to one of the electrodes, and thus, they are capacitatively
summed across the gap to form the bisinusoidal DIMS
waveform at frequency of 2 MHz.34 DIMS spectra were
acquired by scanning the CV using a LabVIEW program linked
to the instrument control software. Ten mass spectra were
averaged for each CV in the DIMS spectra. A static CV for the
filter mode can also be selected with the LabVIEW program.
The MS/MS spectra shown for the filter mode were averaged
for 1 min at the static CV.
■ RESULTS AND DISCUSSION
Spiked Peptide in a Model Peptide Pool
The model peptide pool that was generated was intended to
simulate a complex mixture of very similar peptides (by
molecular weight, hydrophobicity, and sequence) such as that
which would be seen in a collection of antigen peptides
obtained from a biological source. A DIMS scan of a solution of
the pure “target” peptide, protonated GLR (amino acid
sequence = FLSSANEHL), was performed to determine the
optimum CV for selection of this peptide. The DIMS spectrum
is shown in Figure 3. At a DV of 1200 V, the optimum CV was
determined to be 6.5 V.
The MS/MS spectrum obtained for pure GLR (m/z 1017.5)
was compared to that obtained for the mixture of 94 peptides
(Figure 4a). Without GLR spiked into the mixture, none of the
product ions observed from pure GLR were present (Figure
4b). The GLR peptide was spiked into the 94-peptide pool at
concentrations ranging from 1 μM to 1 pM. For each solution
the MS/MS spectrum at the mass-to-charge ratio of the target
protonated GLR peptide was taken with and without DIMS
active. The five most intense product ions observed in the MS/
MS spectrum of pure GLR, [M + H − H2O]+, [M + H −
NH3]
+, [M + H − H2O − NH3]+, b8, and b8-NH3 were used to
evaluate whether GLR was detectable at each concentration.
With 1 pM GLR spiked into the mixture, two of the five
product ions were observable at a signal-to-background ratio
greater than 3, where background is defined as the signal
obtained for the mixture without GLR spiked in. However, the
ratio of these product ions deviated too much from the
reference spectrum to consider the peptide to be detected at
this concentration. With 10 pM GLR spiked into the mixture,
all five of the product ions were observable, with a contaminant
ion present that was observed without GLR (Figure 4c).
Without DIMS, none of the product ions observed at greater
than 5% relative intensity match those observed from MS/MS
of protonated GLR (Figure 4d). Using the detection of five
product ions as indicative of the presence of the target ion (in
typical biomarker detection, only two product ions are used to
confirm the presence of an analyte), a comparison of the
detection of GLR in the peptide mix with and without DIMS
was made (Figure 5a,b). The red line represents the signal
Figure 1. AutoCAD drawing of DIMS assembly.
Figure 2. Simplified schematic of the addition of sinusoidal waves
across the gap to form a bisinusoidal waveform.
Figure 3. DIMS scan of protonated FLSSANEHL (also called GLR
m/z 1017.5) at a DV of 1200 V.
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intensity at which the signal-to-background ratio is equal to 3.
In this model peptide pool, the target antigen was readily
detected at a concentration of 10 pM in a mixture of 94 other
peptides possessing similar chemical properties. Each MS/MS
scan was obtained using a volume of ∼2 μL; so the system is
able to identify peptides at the low attomole level. This level of
sensitivity (20 amol = 1.2 × 107 molecules) is important when
considering applying this technique for use in human cancer
samples. In the case of acute leukemia, most patient samples
have ∼1 × 107 leukemia cells per mL of whole blood with each
cell possessing ∼10,000 HLA molecules. A routine blood draw
of 10 mL would therefore be expected to yield 1 × 1012
peptides, present at various frequencies, making the application
of DIMS−MS/MS for leukemia antigen discovery feasible in
most clinical samples.31,32 In solid tumors, a 1 cm3 sample
contains ∼1 × 108 cells; so again DIMS−MS/MS has the
potential for use in readily accessible clinical specimens.35
Identification of a Known Cancer Associated Antigen, CG1,
Using DIMS−MS/MS
A significant problem in cancer immunology is the
identification of cancer-specific peptide antigens, which can
then be developed into cancer immunotherapeutics, such as
vaccines.12,36,37 To demonstrate how DIMS−MS/MS could be
applied to this problem, the device was used to detect three
known cancer antigens from a model leukemia cell line,
U937.A2. The three peptide antigens targeted, CG1
(FLLPTGAEA), UNC-CDK4-1 (ALTPVVVTL), and UNC-
ANKRD17-1 (LLIERGASL), are (1) derived from proteins
that are overexpressed or aberrantly processed in human acute
myeloid leukemia (AML), (2) computationally predicted to
bind with high affinity to HLA-A*0201 (the most common
Figure 4. MS/MS of protonated FLSSANEHL (GLR), where panel a was obtained for 10 μM FLSSANEHL in 50/49.9/0.1 acetonitrile/water/
formic acid, panels b and c were obtained with DIMS at a DV of 1200 V and a CV of 6.5 V, where panel b was obtained for a mixture of 94 peptides
without FLSSANEHL added, and panel c was obtained for the same mixture of 94 peptides, but with 10 pM FLSSANEHL in the mixture, and panel
d was obtained without DIMS for the mixture of 94 peptides with 10 pM FLSSANEHL.
Figure 5. Sum of the intensities of the five most intense product ions observed from MS/MS of protonated FLSSANEHL as a function of the
concentration of FLSSANEHL (GLR) in the mixture of 94 peptides, where panel a is without DIMS and panel b is with DIMS under the optimum
conditions for the selection of protonated GLR. The red line indicates the signal intensity at which the signal-to-background ratio is 3, where
background is defined as the signal obtained for the mixture of 94 peptides without GLR spiked in.
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HLA type), and (3) have been previously shown to be
presented by U937.A2 cells.23,25,38
The optimum CV to select for sodiated CG1 (FLLPTGAEA
+ Na+, m/z 940.4) at a DV of 1200 V was determined to be 7.8
V from a DIMS scan of the pure peptide (Figure 6a). Note that,
rather than the analysis being performed with the protonated
peptide, the sodiated peptide was used because there was
greater sensitivity with the latter. The sodiated peptide would
likely not be seen in an LC/MS experiment because the LC
effectively “desalts” the sample, and there would be no sodium
present in the solvent to effect ionization when the peptide
eluted. The MS/MS of the pure CG1 peptide is shown in
Figure 6b. MS/MS of sodiated peptides has been extensively
studied, and in general, the fragmentation efficiency is as good
or better than that observed for protonated peptides.39,40 With
DIMS, the peptide cell extract MS/MS spectrum of m/z 940.4
exhibited five product ions that matched the MS/MS of the
pure peptide as well as a contaminant peak (Figure 6c).
Without DIMS, none of the product ions observed at greater
than 5% relative intensity match those observed from the MS/
MS of sodiated CG1 (Figure 6d).
This approach was used for two other previously confirmed
antigen peptides UNC-CDK4-1 (ALTPVVVTL) and UNC-
ANKRD17-1 (LLIERGASL).38 After determining the optimum
CVs for UNC-CDK4-1 and UNC-ANKRD17-1, the same
discovery experiment was performed as described above. In the
case of UNC-CDK4-1, four identifiable product ions could be
detected in the MS/MS with DIMS active and with DIMS
transparent (Supplementary Figure S-1 a-c). For UNC-
ANKRD17-1, one identifiable product ion could be assigned
on the MS/MS with DIMS active, and no product ions could
be identified without DIMS (Supplementary Figure S-2 a-c).
With one observed product ion, we believe we have detected
this peptide but cannot confirm its detection due to the lack of
additional product ions and inability to perform MS3 due to low
ion intensity. In all 3 peptides tested, DIMS−MS/MS
performed as well or better than MS/MS alone. Multiple
product ions from the MS/MS spectra could be identified with
DIMS active for both CG1 and UNC-CDK4-1.
■ CONCLUSIONS
Many human tumors are susceptible to T-cell mediated killing;
however, to avoid off-target toxicity, T-cell immunotherapeutics
such as vaccines or adoptive cellular therapy must target specific
cancer-associated antigens.12,36,41−43 Nontargeted HPLC−MS
has typically been used to identify these antigens.15−17,19,20 In
this work we demonstrate that cancer antigens can be identified
using a targeted MS approach, aimed at identifying specific
antigens, and that DIMS significantly improved our ability to
confirm the presence of antigens by improving the signal-to-
noise of the MS experiments.
Cancer antigen discovery using nontargeted MS methods
have typically required extremely large cell populations of >1 ×
109 cells per analysis, which makes analysis of most clinical
samples impossible.19 While we originally expanded >1 × 109
U937.A2 cells, the isolated peptides were divided into 10
aliquots so that the antigen discovery experiments were
performed on peptides from ∼1 × 108 cells, a number of
cells that can be obtained in many more clinical specimens,
particularly AML samples.35 The ability to detect antigens using
these small quantities of cellular material is a result of our
targeted approach to antigen discovery and the improved
signal-to-noise of the DIMS device, which we observed in all
experiments, when used in a targeted antigen discovery
method.
Over the past two decades, computational algorithms have
greatly enhanced our ability to predict cancer antigens.22−26
Figure 6. (a) DIMS scan of sodiated FLLPTGAEA (m/z 940.6) and MS/MS obtained for sodiated FLLPTGAEA, where panel b was obtained for
10 μM FLLPTGAEA in 50/49.9/0.1 acetonitrile/water/formic acid, panel c was obtained for the peptide cell extract with DIMS with a DV of 1200
V and a CV of 7.8 V, and panel d was obtained for the peptide cell extract without DIMS.
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With this advancement, targeted MS approaches, as described
in this article, can now be used to screen for and identify high
value cancer antigens. This approach is particularly exciting
given the dramatic expansion of cancer genome sequencing.44
With these types of genomic data, it is possible to probe patient
tumor genomes and predict candidate antigens that result from
genetic lesions in the tumor itself.27 DIMS−MS/MS could then
be applied to specific patient samples to confirm or deny the
presence of the predicted antigen, which could lead to more
informed decisions regarding possible cancer immunotherapies.
Modifications to our current device could include further
optimization of the DIMS electrodes to improve focusing of the




Peptide sequences, molecular weights, and predicted HLA-
A*0201 binding affinities for the 95 peptides in the peptide
pool. MS/MS spectra with and without DIMS for two of the
previously identified cancer antigens in the cell extract (UNC-
CDK4-1 and UNC-ANKRD17-1). This material is available
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